[go: up one dir, main page]

MX2013001361A - 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. - Google Patents

4-(1h-indol-3-il) - pirimidina como inhibidores de alk.

Info

Publication number
MX2013001361A
MX2013001361A MX2013001361A MX2013001361A MX2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A MX 2013001361 A MX2013001361 A MX 2013001361A
Authority
MX
Mexico
Prior art keywords
pyrimidines
indol
alk inhibitors
formula
methods
Prior art date
Application number
MX2013001361A
Other languages
English (en)
Inventor
Brian Aquila
Timothy Pontz
Bo Peng
Victor Kamhl
Jamal Carlos Saeh
Kumar Thakur
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2013001361A publication Critical patent/MX2013001361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y/o Fórmula (la): (Ver Formulas) y a sus sales, composiciones farmacéuticas, métodos de empleo y métodos para su preparación. Estos compuestos inhiben la actividad cinasa de ALK y, por lo tanto, se pueden utilizar para tratar el cáncer.
MX2013001361A 2010-08-02 2011-08-02 4-(1h-indol-3-il) - pirimidina como inhibidores de alk. MX2013001361A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07
PCT/GB2011/051465 WO2012017239A2 (en) 2010-08-02 2011-08-02 Chemical compounds

Publications (1)

Publication Number Publication Date
MX2013001361A true MX2013001361A (es) 2013-05-17

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001361A MX2013001361A (es) 2010-08-02 2011-08-02 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.

Country Status (14)

Country Link
US (1) US8461170B2 (es)
EP (1) EP2601186A2 (es)
JP (1) JP2013534221A (es)
KR (1) KR20130096241A (es)
CN (1) CN103153982A (es)
AR (1) AR089550A1 (es)
AU (1) AU2011287386A1 (es)
BR (1) BR112013002587A2 (es)
CA (1) CA2805827A1 (es)
MX (1) MX2013001361A (es)
RU (1) RU2013109132A (es)
TW (1) TW201219383A (es)
UY (1) UY33539A (es)
WO (1) WO2012017239A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3009431T (pt) 2011-07-27 2017-12-26 Astrazeneca Ab Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro
CN102899882B (zh) * 2012-11-07 2014-08-06 西南大学 超亲水涤纶织物的磷酸制备方法
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN105085550B (zh) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 一类alk激酶抑制剂及其制备方法
EP3157916B1 (en) * 2014-06-19 2018-12-12 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
JP6606278B2 (ja) * 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
SG11201809751XA (en) 2016-05-26 2018-12-28 Zeno Royalties & Milestones Llc Egfr inhibitor compounds
PT3514153T (pt) * 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo
US11931536B2 (en) * 2017-07-26 2024-03-19 Dk Medical Technology Co., Ltd. Surface liquefied drug-coated balloon
JP7367908B2 (ja) * 2018-04-09 2023-10-24 上海科技大学 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
MX2021011810A (es) 2019-03-29 2021-10-26 Astrazeneca Ab Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as.
KR20210002015A (ko) * 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN116763792B (zh) * 2023-06-19 2024-03-12 西安国际医学中心医院 Hg-14-10-04在制备治疗食管鳞癌的药物中的应用
TW202509078A (zh) 2023-07-07 2025-03-01 美商維里迪恩醫療股份有限公司 治療慢性甲狀腺眼病之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
JP2009520785A (ja) 2005-12-23 2009-05-28 アストラゼネカ アクチボラグ 抗菌性のピロロピリジン、ピロロピリミジン、及びピロロアゼピン
CA2659582A1 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US8093239B2 (en) * 2007-06-01 2012-01-10 Glaxosmithkline Llc Imidazopyridine kinase inhibitors
WO2009024824A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2010049731A1 (en) 2008-10-29 2010-05-06 Astrazeneca Ab Pyrazolo- and imidazopyridinylpyrimidineamines as igf-1r tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN103153982A (zh) 2013-06-12
US20120028924A1 (en) 2012-02-02
AU2011287386A1 (en) 2013-03-07
AR089550A1 (es) 2014-09-03
JP2013534221A (ja) 2013-09-02
US8461170B2 (en) 2013-06-11
KR20130096241A (ko) 2013-08-29
WO2012017239A3 (en) 2012-04-05
WO2012017239A2 (en) 2012-02-09
BR112013002587A2 (pt) 2019-09-24
EP2601186A2 (en) 2013-06-12
CA2805827A1 (en) 2012-02-09
UY33539A (es) 2012-02-29
RU2013109132A (ru) 2014-09-10
TW201219383A (en) 2012-05-16

Similar Documents

Publication Publication Date Title
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
UA109010C2 (en) Morpholino pyrividines and their use in therapy
PH12013500265A1 (en) Pharmaceutically active compounds as axl inhibitors
MY199894A (en) Prmt5 inhibitors and uses thereof
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PH12012502334A1 (en) Heteroaryl imidazolone derivatives as jak inhibitors
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
IN2014CN04530A (es)
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
PH12013502516A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal